29 citations
,
August 2007 in “Annals of Oncology” Docetaxel and oxaliplatin are effective and have manageable side effects for recurrent platinum-sensitive ovarian cancer.
December 2025 in “Drug Design Development and Therapy” This retrospective study reported that in HER-2-negative metastatic breast cancer patients, anlotinib combined with taxane/capecitabine showed superior disease control rate, progression-free survival, and overall survival compared to bevacizumab plus chemotherapy, with both treatments having tolerable safety profiles.
1 citations
,
August 2023 in “Acta dermato-venereologica” This study found that corticosteroids were the most common treatments for alopecia areata in the USA, but the substantial disease burden suggests a need for more effective options.
May 1993 in “Drugs & Therapy Perspectives” Formestane is a preferred second-line treatment for advanced breast cancer in postmenopausal women because it's effective and has fewer side effects.
January 2012 in “Zhongguo quanke yixue” This study found that S-1 combined with paclitaxel was an effective and tolerable second-line chemotherapy option for advanced gastric cancer, with some patients experiencing partial responses and manageable adverse reactions.
